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Melanocortin receptor 1 (MC1R) is overexpressed in melanoma and may be a molecular tar-
get for imaging and peptide receptor radionuclide therapy. 68Gallium (68Ga) labeling of
DOTA-conjugated peptides is an established procedure in the clinic for use in positron emis-
sion tomography (PET) imaging. Aim of this study was to compare a standard labeling proto-
col against the 68Ga-DOTA peptide purified from the excess of unlabeled peptide.
Procedures
The MC1R ligand DOTA-NAPamide was labeled with 68Ga using a standard clinical proto-
col. Radioactive peptide was separated from the excess of unlabeled DOTA-NAPamide by
HPLC. Immediately after the incubation of peptide and 68Ga (95˚C, 15 min), the reaction
was loaded on a C18 column and separated by a water/acetonitrile gradient, allowing frac-
tionation in less than 20 minutes. Radiolabeled products were compared in biodistribution
studies and PET imaging using nude mice bearing MC1R-expressing B16/F1 xenograft
tumors.
Results
In biodistribution studies, non-purified 68Ga-DOTA-NAPamide did not show significant
uptake in the tumor at 1 h post injection (0.78% IA/g). By the additional HPLC step, the
molar activity was raised around 10,000-fold by completely removing unlabeled peptide.
Application of this rapid purification strategy led to a more than 8-fold increase in tumor
uptake (7.0% IA/g). The addition of various amounts of unlabeled DOTA-NAPamide to the
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purified product led to a blocking effect and decreased specific tumor uptake, similar to the
result seen with non-purified radiopeptide. PET imaging was performed using the same
tracer preparations. Purified 68Ga-DOTA-NAPamide, in comparison, showed superior
tumor uptake.
Conclusions
We demonstrated that chromatographic separation of radiolabeled from excess unlabeled
peptide is technically feasible and beneficial, even for short-lived isotopes such as 68Ga.
Unlabeled peptide molecules compete with receptor binding sites in the target tissue. Purifi-
cation of the radiopeptide therefore improved tumor uptake.
Introduction
Cutaneous malignant melanoma is one of the most lethal forms of cancer. Its incidence is
increasing rapidly, making it a significant public health threat [1]. Melanocortin receptor 1
(MC1R) is overexpressed in most melanomas, making it a promising molecular target for diag-
nosis and peptide receptor radionuclide therapy (PRRT) [2]. Because of their low molecular
weight, low immunogenicity and excellent tumor penetration, radiopeptides have attracted a
steadily increasing interest in receptor-mediated tumor targeting [3, 4].
Because of its enhanced spatial resolution and high sensitivity, positron emission tomogra-
phy (PET) has been developed into a valuable diagnostic tool, particularly for the detection of
small metastases. Since commercial 68Germanium/68Gallium generators became widely avail-
able, 68Ga labeling of chelator-conjugated peptides turned into an established clinical proce-
dure for use in PET imaging [5]. Due to its short half-life (67.71 min), 68Gallium (68Ga) has a
higher molar activity (lower mass/activity ratio) than other nuclides in nuclear medicine,
resulting in an unfavorable reaction stoichiometry [6]. In the radiochemical chelation process
of 68Ga incorporation into 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a
high molar excess of DOTA-conjugated peptide over radiometal is usually used to attain high
68Ga complexation yields. The applied excess of cold peptide mass for 68Ga chelator loading
typically ranges from 1,000-fold to 10,000-fold. This fraction is usually not removed before
injection into the patient and it may compete for binding sites at the tumor, resulting in lower
detection sensitivity. The aim of this study was to compare a standard labeling protocol against
a labeling and HPLC purification protocol, which removes the excess of unlabeled peptide. We




DOTA-NAPamide (Acetyl-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys(DOTA)-NH2), an MC1R-
binding peptide analogue described by Froidevaux et al. [7] was from ABX (Radeberg, Ger-
many), [Nle4,d-Phe7]-melanocyte-stimulating hormone (NDP-MSH) from peptides&ele-
phants (Hennigsdorf, Germany). To confirm the presence of the correct molecular mass,
peptides were analyzed by a Finnigan Surveyor MSQ Plus liquid chromatography/mass spec-
trometry (LC-MS) system (Thermo Finnigan, Bremen, Germany). Peptides were used at a
purity of greater than 95%.
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Competitive binding and saturation assays with 125I-NDP-MSH
[Nle4,d-Phe7]-melanocyte-stimulating hormone (NDP-MSH) was iodinated with Na125I by
the chloramine-T method and it was purified from unlabeled peptide by HPLC as described
before [8]. Saturation and competitive binding studies were performed with live cells. 40.000
B16/F1 cells were seeded per well into a 96-well flat bottom cell culture plate. For competitive
binding, medium was removed and 50 μL of binding buffer (50 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.5% BSA, pro-
tease inhibitor cocktail cOmplete [Roche Applied Science, Penzberg, Germany]) with increas-
ing concentrations of non-radioactive peptide was added to the cells. Additionally, 50 μL
binding buffer with 100,000 counts per minute (cpm) of 125I-NDP-MSH was added. After 30
minutes of incubation at 37˚C, cells were washed 4 times with cold washing buffer (50 mM
Tris-HCl pH 7.4, 125 mM NaCl, 0.05% BSA). 100 μL 1 N NaOH was added to lyse cells.
Lysates were transferred into vials and measured using a gamma counter (Wallac 1470 Wizard,
PerkinElmer, Waltham, MA, USA). The saturation assay was performed by adding 100 μL of
binding buffer with increasing amounts of 125I-NDP-MSH to the cells in the presence or
absence of 1 μM of unlabeled NDP-MSH.
Radiolabeling of DOTA-NAPamide
Radiolabeling experiments were performed on a Modular Lab PharmTracer synthesis module
(Eckert & Ziegler, Berlin, Germany) which allows fully automated cassette-based labeling of
gallium tracers utilizing a pharmaceutical grade 68Ge/68Ga generator (GalliaPharm, 1.85 GBq,
good manufacturing practice (GMP)-certified; Eckert & Ziegler GmbH, Berlin, Germany).
Cassettes were GMP-certified and sterile. They were used without pre-conditioning of the car-
tridges. Gallium generator at three months post calibration was eluted with aqueous HCl (0.1
M, 7 mL) and the eluate was purified on an ion-exchange cartridge followed by elution using 1
mL of 0.1 M HCl in acetone. An aliquot of DOTA-NAPamide, 50 μg (stock solution 1 mg/mL
in 10% DMSO, 90% water) was mixed with 500 μL 0.1 M HEPES buffer (pH 7) and heated for
500 s at 95˚C. After the reaction, the reactor was cooled with 500 μL of saline and, without
post-processing, the contents of the reactor were directly used for subsequent HPLC
purification.
HPLC purification
68Ga-labeled peptide was separated from non-radioactive NAPamide by reverse phase HPLC
on an Agilent 1200 system (Agilent, Waldbronn, Germany). The complete mixture from the
reaction chamber was loaded on an Eclipse XDB-C18 bonded silica column (Agilent, Wald-
bronn, Germany) and eluted with a linear gradient of acetonitrile (gradient 15–45% B in A
over 20 min, flow rate of 1 mL/min, solvent A water + 0.1% trifluoroacetic acid (TFA), solvent
B acetonitrile + 0.1% TFA, column at 55˚C). 68Ga-DOTA-NAPamide was detected using a
FlowStar LB513 detector (Berthold, Bad Wildbad, Germany) equipped with a BGO-X (5 μL)
chamber. The unlabeled peptide moiety was detected via a diode array absorbance detector.
68Ga-DOTA-NAPamide was separated with the help of an automated fraction collector.
Competitive binding with 68Ga- DOTA-NAPamide
Competitive binding studies were performed according the procedure described for
125I-NDP-MSH. B16/F1 cells were incubated with 20 kBq (0.2 fmol) per well of purified 68Ga-
DOTA-NAPamide alone or with 1,000-fold (0.2 pmol) or 10,000-fold (2 pmol) excess of non-
radioactive DOTA-NAPamide.
HPLC purification of 68Ga-DOTA-NAPamide
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Tumor inoculation and animal care
The study protocol for in vivo biodistribution and in vivo PET/MRI imaging was approved by
the local committee at Landesamt fu¨r Gesundheit und Soziales for animal care according to
the German law for the protection of animals. All applicable institutional and national guide-
lines for the care and use of animals were followed. 23 NMRI-Foxn1nu /Foxn1nu mice (Janvier
Le Genest-Saint-Isle, France) were used in in vivo biodistribution experiments and 4 mice
were used for PET/MRI imaging. Mean weight of the animals used was 28 gram. Mice were
kept under SPF conditions with 12h/12h light/dark cycle at the animal facility of Charite´ –Uni-
versita¨tsmedizin Berlin, Campus Virchow-Klinikum. Animal health was checked at least twice
weekly by visual inspection of general appearance, behavior, feces, tumor inoculation sites and
by weighing the animals. A score sheet was applied to monitor health status and to take action
in case a humane endpoint would be reached. During this study, humane endpoints were not
reached. The maximum tumor size was below one cm3. Analgesics had not to be used for this
study. Isoflurane was used as an anesthetic. Animals were sacrificed by cervical dislocation
under isoflurane anesthesia. No mortality occurred outside of planned euthanasia. Data
reporting was done according to ARRIVE guidelines (see S1 File).
The B16/F1 murine melanoma cell line xenograft model was chosen as it represents the
standard and most frequently used tumor model for MC1R targeting in mice. This model has
previously been shown to express relevant amounts of mouse MC1R. As both mouse and
human MC1R bind NAPamide with similar affinity, this model is relevant to human biology.
Experiments were performed throughout the day, between 9 am and 8 pm at Berlin Experi-
mental Radionuclide Imaging Center (BERIC), Charite´ –Universita¨tsmedizin Berlin. Animals
were randomly allocated to the experimental groups.
In vivo biodistribution assays
B16/F1 cells (3x106) in a volume of 150 μL 0.9% NaCl were inoculated subcutaneously on the
right shoulder of NMRI-Foxn1nu /Foxn1nu mice (Janvier Labs, Saint-Berthevin, France). After
1–2 weeks of growth, tumor bearing mice were injected with approximately 5 MBq of 68Ga-
DOTA-NAPamide in a volume of 100 μL 0.9% NaCl into a lateral tail vein via a catheter. Mice
were sacrificed and dissected 1 h after injection. The B16F1 tumor, blood, stomach, pancreas,
small intestine, colon, liver, spleen, kidney, heart, lung, muscle and femur samples were
weighed and uptake of radioactivity was measured by a gamma counter (Wallac 1470 Wizard,
Perkin Elmer, Waltham, MA, USA). To determine the effect of unlabeled ligand on tumor
uptake, either 50 pmol or 500 pmol non-labeled DOTA-NAPamide were co-injected.
In vivo PET/MRI imaging
B16/F1 cells (3x106) in a volume of 150 μL 0.9% NaCl were inoculated subcutaneously on the
right shoulder of NMRI-Foxn1nu /Foxn1nu mice (Janvier Labs, Saint-Berthevin, France). After
1–2 weeks of growth, tumor bearing mice were injected with approximately 15 MBq of 68Ga-
DOTA-NAPamide in a volume of approximately 150 μL 0.9% NaCl into a lateral tail vein via a
catheter. Positron emission tomography (PET) / magnetic resonance imaging (MRI) (1 Tesla
nanoScan PET/MRI Mediso, Budapest, Hungary) was performed at Berlin Experimental
Radionuclide Imaging Center (BERIC), Charite´ –Universita¨tsmedizin Berlin. Anatomic
MRI scans were acquired using a T2-weighted 2D fast spin echo sequence (T2 FSE 2D)
with the following parameters: coronal sequentially, matrix 256x256x20 with dimensions
0.36x0.36x1.5mm3, TR: 8695 ms, TE: 103 ms, and a flip angle of 180˚. PET scans were per-
formed for 90 min starting directly before intravenous injection of tracer. PET images were
reconstructed from the raw data with the following image sequence: 6 x 10 s, 6 x 30 s, 5 x 60 s
HPLC purification of 68Ga-DOTA-NAPamide
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and 8 X 600 s. The tracer standardized uptake value (SUV) in the tumor tissue was determined
by manual contouring of a volume of interest (VOI) of the PET images using PMOD 3.610
(PMOD Technologies, Zu¨rich, Switzerland).
Results
DOTA-NAPamide binds to MC1R in vitro
To confirm MC1R expression in the melanoma cell line B16/F1 and to assess the affinity of
DOTA-NAPamide towards the receptor, competitive radioligand binding and saturation
binding assays using 125I-labeled NDP-MSH were performed (Fig 1A). DOTA-NAPamide
showed a high affinity for the murine MC1R expressed in the B16/F1 cells, with a calculated Ki
of 0.37 nM (95% CI 0.24 nM, 0.57 nM) and a KD of 0.66 nM (95% CI 328 pM, 992 pM). To
exclude a negative effect of gallium (Ga) incorporation into the DOTA chelator on binding
affinity, competitive in vitro binding assays were performed using either DOTA-NAPamide or
DOTA-NAPamide complexed with non-radioactive Ga. Fig 1B shows nearly identical concen-
tration-response curves and Ki values: 0.40 nM (95% CI 0.18 nM, 0.86 nM) vs. 0.43 nM (95%
CI 0.21 nM, 0.88 nM) for unlabeled and Ga-labeled DOTA-NAPamide binding to B16/F1
cells. This demonstrated that chelation with Ga did not affect the affinity of DOTA-NAPamide
towards the MC1R receptor.
Unlabeled DOTA peptide can be removed by HPLC
For removal of unlabeled excess of DOTA-NAPamide and of non-incorporated 68Ga after
completion of the radiochemical reaction, the product was transferred from the reactor to an
HPLC equipped with a C18 reverse-phase column and a fraction collector. Fig 2A shows an
exemplary separation run for 68Ga-DOTA-NAPamide and unlabeled DOTA-NAPamide. Free
68Ga does not exhibit a distinct interaction with the C18 column and elutes close to the dead
time of the HPLC. For the labeling reaction, the peptide was used in an excess compared to
68Ga (10,000:1 molar ratio) and it showed a slightly prolonged retention time in comparison to
Fig 1. DOTA-NAPamide and Ga-DOTA-NAPamide are high affinity ligands for the melanocortin 1 receptor (MC1R): 125I-NDP-MSH ligand
displacement and saturation assays performed with whole B16/F1 cells. A Various concentrations of NAPamide were used to displace 125I-NDP-MSH. The
inset shows a saturation experiment to determine the dissociation constant. B 125I-NDP-MSH ligand displacement assay to assess the impact of gallium
chelation on DOTA-NAPamide. Curve fits were performed in GraphPad Prism by applying a one-site binding equation. (n = 3; mean +/- SEM).
https://doi.org/10.1371/journal.pone.0217883.g001
HPLC purification of 68Ga-DOTA-NAPamide
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68Ga-DOTA-NAPamide. This was exploited to purify 68Ga-DOTA-NAPamide (Fig 2A). To
demonstrate that an excess of unlabeled peptide would displace 68Ga-DOTA-NAPamide from
its receptor, the radiotracer was incubated on B16/F1 cells in vitro either alone or with a
1,000-fold or 10,000-fold excess of DOTA-NAPamide (Fig 2B). Indeed, both concentrations of
unlabeled peptide were able to displace the radiopeptide as compared to incubation with
buffer. In comparison to purified tracer alone, a 1,000-fold excess led to an approximately 20%
decrease and a 10,000-fold excess of unlabeled peptide diminished the overall binding to less
than 50% (Fig 2B).
Purification of the tracer leads to an improved tumor uptake
Fig 3 shows the results of an in-vivo biodistribution experiment in B16/F1 xenograft-bearing
mice 1 hour after i.v. injection of 68Ga-DOTA-NAPamide. The non-purified tracer from the
standard procedure showed a very low uptake into subcutaneously grown B16/F1 tumor xeno-
grafts (0.78% ± 0.55% IA/g [95% CI]). Removal of unlabeled DOTA-NAPamide led to a more
than 8-fold increase in tumor uptake, with 7.0% ± 1.7% IA/g [95% CI] in the tumor for the puri-
fied 68Ga-DOTA-NAPamide. Except for a moderate uptake in the kidneys, all other tissues
showed only a small uptake of the tracer, mostly below 0.5% IA/g. In animals treated with 68Ga-
DOTA-NAPamide produced by the standard procedure, the kidney uptake was slightly higher
compared to the purified tracer (4.6% ± 2.7% IA/g vs. 3.0% ± 0.6% IA/g [95% CI]) (Fig 3).
Tumor uptake enhancement is reversed by coinjection of unlabeled peptide
The effect of cold peptide mass was studied by injecting a constant amount of purified 68Ga-
DOTA-NAPamide together with different amounts of unlabeled DOTA-NAPamide. Mice
Fig 2. A Reverse-phase HPLC chromatogram of a 68Ga-DOTA-NAPamide purification. The dashed line shows the radiodetector signal and the peak there
represents the 68Ga-DOTA-NAPamide fraction, while the solid line shows the 280 nm absorption signal with the peak of DOTA-NAPamide. The area
surrounded by dotted lines represents the purified fraction used in in vivo experiments. B In vitro displacement of 68Ga-DOTA-NAPamide from B16/F1 cells
by an excess of unlabeled DOTA-NAPamide (n = 3; mean +/- SEM). Differences were not statistically significant (p = 0.12, R2 = 0.51, one-way ANOVA).
https://doi.org/10.1371/journal.pone.0217883.g002
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were injected with 5 MBq (~50 fmol) alone or with an additional 1,000-fold (50 pmol) or
10,000-fold (500 pmol) excess of unlabeled peptide. This 10,000-fold excess of unlabeled pep-
tide corresponds to the molar ratio in the standard protocol. The coinjection of DOTA-NAPa-
mide led to significant loss of uptake in the MC1R-expressing B16/F1 tumor xenografts (Fig
4). While purified 68Ga-DOTA-NAPamide showed an uptake of 6.7% ± 1.9% IA/g [95% CI],
coinjection of 50 pmol cold DOTA-NAPamide decreased the total uptake to 3.8% ± 3.6% IA/g
[95% CI]. 500 pmol coinjected peptide led to an approximately 6-fold decrease to 1.1% ± 0.5%
IA/g [95% CI] (Fig 4).
PET imaging confirms the results of biodistribution studies
Mice bearing subcutaneous B16/F1 tumors on their right shoulder were injected with approxi-
mately 15 MBq 68Ga-DOTA-NAPamide in different formulations. Each mouse was given a
different DOTA-NAPamide composition (A standard procedure, B purified, C purified
+ 1,000-fold excess of cold peptide, D purified + 10,000-fold excess of cold peptide). Dynamic
PET images were taken from 5 to 90 minutes after injection and tracer standardized uptake
value (SUV) in the tumor tissue was determined by manual contouring of a volume of interest
(VOI). Fig 5 shows all four tested conditions at 1 h post injection. The tumor showed an
increase in uptake of 68Ga-DOTA-NAPamide for the purified (SUV 0.420) and the purified
+ 1,000-fold excess of cold peptide (SUV 0.367) conditions (Fig 5B and 5C). For the injections
with a 10,000-fold excess of unlabeled peptide, the tracer uptake (SUV 0.152) was on a simi-
larly low level as for the unpurified tracer (SUV 0.119) (Fig 5A and 5D). Since the peptide is
excreted through the kidneys into the bladder, a high signal was observed in both organs (kid-
neys not visible in Fig 5 due to their location in a different plane).
Fig 3. Biodistribution at 1 h after i.v. injection of approximately 5 MBq radiotracer. Results of 68Ga-
DOTA-NAPamide produced by the standard protocol (n = 7) are shown in light gray, and results obtained with the
purification protocol (n = 7) are shown in dark gray (mean +/- SEM; ����p = 0.0001, two-way ANOVA followed by
Bonferroni post-test).
https://doi.org/10.1371/journal.pone.0217883.g003
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PLOS ONE | https://doi.org/10.1371/journal.pone.0217883 June 4, 2019 7 / 13
Tracer kinetics
To obtain kinetic profiles, mice were imaged for up to 90 minutes after injection of any of the
four different tracer formulations. Images were reconstructed over short intervals: 10/30/60
seconds until 10 minutes p.i. and over 10 minutes thereafter. Fig 6A shows the kinetics for the
purified 68Ga-DOTA-NAPamide. After defining VOIs for the tumor in each mouse, the
Fig 4. 68Ga-DOTA-NAPamide biodistribution at 1 h after i.v. injection of approximately 5 MBq radiotracer.
Purified 68Ga-DOTA-NAPamide was injected either alone or in parallel with an excess of unlabeled
DOTA-NAPamide (1,000-fold or 10,000-fold excess over radiotracer) (n = 3 per group; mean +/- SEM; ����p = 0.0001,
two-way ANOVA followed by Bonferroni post-test).
https://doi.org/10.1371/journal.pone.0217883.g004
Fig 5. Coronal sections from MRI and PET scans of mice bearing B16/F1 tumors on the right shoulder at 1 h after tail vein
injection of 68Ga-NAPamide with various ratios of labeled and unlabeled peptide. A T2-weighted MRI (corresponding to PET
image in B) B unpurified 68Ga-DOTA-NAPamide C HPLC-purified 68Ga-NAPamide D HPLC-purified 68Ga-NAPamide
+ 1,000-fold excess of DOTA-NAPamide, and E HPLC-purified 68Ga-NAPamide + 10,000-fold excess of DOTA-NAPamide.
https://doi.org/10.1371/journal.pone.0217883.g005
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resulting SUVs were plotted over time from dynamic PET data. Early tracer kinetics in the
tumor confirm the advantage of tracer purification: in the first 5–10 minutes after injection,
the tracer reaches a maximum level in the tumors for all tested conditions (Fig 6B). Thereafter,
uptake was slowly decreasing over the next 90 minutes. In the animal treated with a 1,000-fold
excess of cold peptide mass, the initial amount of radioactivity in the tumor is slightly higher
(SUV 0.63) than in the other tumors (mean SUV 0.43). Of note, the slope of tracer decrease in
B16/F1 tumors was less steep for the purified 68Ga-DOTA-NAPamide.
Discussion
The feasibility of targeting metastatic melanoma with MC1R ligands for nuclear medicine has
been studied as early as 1990 and has since resulted in a multitude of ligand-chelator conju-
gates applied for biodistribution, SPECT and PET experiments [9, 10]. Froidevaux et al. devel-
oped the 8mer metabolically stable high-affinity MC1R ligand DOTA-NAPamide that showed
favorable biodistribution and tumor uptake values ranging from 7.56% to 9.43% IA/g at 4 h p.
i. [7]. The radionuclides used were of moderate half-life (2.81 d for 111In, 3.26 for 67Ga).
Another study with 64Cu-DOTA-NAPamide reported ~4% IA/g at 4 h p.i. [11]. Only recently,
one study used the short-lived 68Ga with this tracer demonstrating tumor demarcation in PET
imaging yet not reporting biodistribution data for the B16/F10 tumors used [12]. However, no
clinical study has been reported for the use of MC1R analogs in melanoma imaging so far.
In experiments preceding this study, we performed biodistribution studies using the MC1R
ligands 68Ga-DOTA-NDP-MSH and 68Ga-DOTA-NAPamide in the B16/F1 melanoma
model, yet failed to achieve the high tumor uptake previously reported for the longer-lived
111In and 67Ga complexes. We hypothesized that the unfavorable stoichiometry of the chela-
tion reaction of the peptide conjugate with 68Ga and the resulting high excess of unlabeled
ligand prevented higher tumor uptake due to competition for MC1R binding sites. Therefore,
Fig 6. A Short-interval reconstruction from dynamic PET data of a mouse bearing a B16/F1 tumor on the right shoulder after tail vein injection of 5 MBq
purified 68Ga-NAPamide. Injected peptide amounts: 500 pmol (unpurified and 10,000-fold excess), 50 pmol (1,000-fold excess) and 0.05 pmol (purified). B
Time-activity relationships of 68Ga-DOTA-NAPamide B16/F1 tumor accumulation derived from dynamic PET data obtained after injection of four different
tracer formulations (n = 1).
https://doi.org/10.1371/journal.pone.0217883.g006
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in the current study we aimed to compare a standard 68Ga labeling protocol against a labeling
and HPLC-purification protocol, which removes the excess of unlabeled peptide. We investi-
gated the influence of peptide mass/molar activity on tumor accumulation of the MC1R ligand
68Ga-DOTA-NAPamide using biodistribution and PET imaging.
For the standard labeling protocol used in this study, the product of 350 MBq 68Ga-
DOTA-NAPamide (3.5 pmol 68Ga) is accompanied by 35 nmol (50 μg) of unlabeled peptide,
resulting in a 10,000-fold excess over the radioligand. Due to this stoichiometry, the theoretical
molar activity of 103,000 GBq/μmol for pure 68Ga-DOTA-NAPamide is diminished to an
effective molar activity of just 10 Gbq/μmol. Lowering the peptide amount in the chelation
reaction was no remedy as it dramatically reduces the radiochemical yield.
HPLC purification of the radiopeptide, however, improved tumor uptake in biodistribution
studies by a factor of more than 8-fold, resulting in a tumor-to-kidney ratio of 2.33 and tumor-
to-tissue ratios of better than 15 for all other organs investigated (Fig 3). While others have
argued HPLC purification was not convenient in clinical practice and developed solid phase
extraction of 68Ga-exendin as an alternative method [13], we found using an HPLC to frac-
tionate tracer was feasible and efficient. In an in vitro binding assay (Fig 2B), however, the dif-
ferences between purified tracer and combinations with either a 1,000-fold or 10,000-fold
excess of unlabeled peptide were less pronounced than expected (only 50% reduction). Adding
a 10,000-fold higher amount of competitor should lead to a higher reduction in binding (e.g.
to about 10%). The lack of a more drastic reduction may be explained by non-specific binding
to the cells e.g. hydrophobic interaction with unrelated cell surface receptors. The impact of
this, however, seemed to be restricted to the in vitro situation, as the in vivo competition (Fig
4) led to a considerably higher displacement (more than 8-fold difference).
As most radiochemical laboratories have this instrumentation in place for routine quality
control, cost may not be limiting. The procedure can also be performed rapidly—within 15 to
20 min. Similar successful approaches to purify 11C, 18F and 67Ga tracers have been reported
[14–16]. However, with production of 68Ga tracers shifting towards kit preparation, HPLC
purification may not have much clinical future. Whether the HPLC purification strategy is
applicable with other tracers needs to be established on a case-to-case basis. We have
attempted to apply this method with a CMKLR1-targeting peptide but failed to improve
tumor uptake above the level of unpurified tracer (about 6%, unpublished results). In addition,
the enhancement of molar activity may not be of critical importance for the imaging of
humans as the applied amount of activity (and thus, peptide) is several orders of magnitude
lower than for rodents. A human of 70 kg mass (2,500 times that of a 28-gram mouse) and 7
liters of blood volume (4,400 times that of the mouse) would typically receive about 150 MBq
instead of 15 MBq for mice in this study (only 10-fold more). Consequently, the resulting con-
centration of the competing peptide would be much lower in the clinical setting.
The appropriate amount of cold peptide mass or the best molar activity for optimal tumor
imaging has been a matter of investigation for more than two decades now. Using the somato-
statin receptor ligand 111In-pentetreotide, an early study by Breeman et al. found moderate
molar activities (0.6, 6.0 MBq/μg) to yield the highest uptake in rat pancreas, while higher and
lower values showed reduced uptake.[17] However, the majority of subsequent studies demon-
strated that for efficient receptor targeting, low peptide doses should be administered. De Jong
et al e.g. systematically investigated the effects of varying peptide mass at constant or varying
molar activity on organ activity using 111In- [DOTA0,Tyr3]octreotide in tumor-bearing rats
[18]. This study identified a principal detrimental effect of increasing peptide doses in both
experimental settings with pancreas and tumor only showing limited benefit of an increased
peptide dose of 0.2 (pancreas) or 0.5 μg (CA20948 tumors). Increasing amounts of radiola-
beled peptide at constant molar activity were also used investigating the 67Ga-labeled GRPR
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ligand BZH3 [19]. A peptide amount of 15 pmol per mouse showed highest tumor uptake
(10.9% IA/g), with 5, 45 and 135 pmol yielding somewhat lower results (7.98, 8.0, 6.25% IA,
respectively). Of note, intestines showed a continuously decreasing % IA/g uptake with
increasing amounts of peptide, suggested to be due to increasing saturation of receptors. With
limited molar activity of the 68Ga tracer, significant peptide dose reduction was only feasible at
the expense of very small activities, insufficient for high-quality imaging in mice.[19]
Brom et al. compared the effect of co-injected unlabeled peptide over 5 orders of magnitude
in in vivo biodistribution studies [13]. Low doses of unlabeled exendin-3, in the molar range of
co-injected radioactive [Lys40(111In)]exendin-3 did not show a clear effect on tumor uptake.
Eventually, the addition of 0.3 μg (~60 pmol) cold peptide led to a decrease in tumor uptake of
the radioactive tracer. This dose was approximately 300-fold higher than the administered
amount of 111Indium-labeled exendin. The same group compared the effect of co-injected
unlabeled DOTA-minigastrin over four orders of magnitude (0.1–100 μg) in in vivo biodistri-
bution studies. They observed an increasing drop in tumor uptake of their labeled DOTA-
minigastrin for all tested amounts of cold co-injections (50 pmol—50 nmol) [20]. Using the
standard labeling procedure in the current study, 500 pmol of unlabeled peptide were injected
with an activity of 5 MBq 68Ga-DOTA-NAPamide. A detrimental effect of higher peptide dose
had also been described in the first study describing DOTA-NAPamide as an MC1R tracer:
tumor uptake at 170 pmol or 420 pmol peptide was much lower than with just 20 pmol [7].
Chelators with higher labeling efficiency than DOTA may represent an alternative approach to
obtaining high molar activities. Recently, the effect of varying molar activities (0.5–1,000 GBq/
μmol) was studied for the two integrin-targeting 68Ga-TRAP peptides 68Ga-aquibeprin and 68Ga-
avebetrin in biodistribution and PET imaging [12]. With this chelator (TRAP), very high molar
activities (up to 5,000 GBq/μmol) could be produced during radiochemical labeling without addi-
tional HPLC purification [21]. Again, highest tumor uptake was found with highest molar activi-
ties with similar tumor-to-kidney ratios for all tested conditions. However, tumor-to-muscle
ratios reached a maximum at 6 nmol (~3.5 GBq/μmol), indicating a benefit for moderate molar
activities when muscle signal is limiting [12]. A variety of factors may lead to this, including target
expression levels in muscle and other organs. Further studies will have to elucidate the relation-
ship between expression, biodistribution and optimal molar activity for tumor imaging.
Conclusions
Choosing the right molar activity and finding a way to obtain it in an efficient way remains to
be a challenge during the introduction of new tracers. We showed that separation of radiola-
beled and cold peptide via HPLC is technically feasible and beneficial, even for short-lived iso-
topes such as 68Ga. Unlabeled peptide molecules can strongly compete with receptor binding
sites in the target tissue. Purification of the radiopeptide improved tumor uptake in in biodis-
tribution studies and PET/MRI scans. Production of higher molar activity radiotracers may
not only be important for imaging, but may also improve uptake and thus efficacy in therapeu-
tic procedures such as PRRT.
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